Global Prostate Cancer Diagnostics Market Growth (Status and Outlook) 2023-2029

Global Prostate Cancer Diagnostics Market Growth (Status and Outlook) 2023-2029

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
LPI (LP Information)' newest research report, the “Prostate Cancer Diagnostics Industry Forecast” looks at past sales and reviews total world Prostate Cancer Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Diagnostics sales for 2023 through 2029. With Prostate Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Diagnostics.
The global Prostate Cancer Diagnostics market size is projected to grow from US$ 13140 million in 2022 to US$ 22650 million in 2029; it is expected to grow at a CAGR of 8.1% from 2023 to 2029.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Diagnostics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segmentation by application
Age Below 55
Age 55-75
Age Above 75
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics

Please note: The report will take approximately 2 business days to prepare and deliver.